NCT04495920View on ClinicalTrials.gov

Clinical Evaluation of the Residual Antimicrobial Activity

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

July 13, 2020

Study Completion Date

July 28, 2020

Conditions
Bacterial Overgrowth
Interventions
DRUG

CGB-S-100

Alcohol and choline geranate

Trial Locations (1)

59718

Bioscience Laboratories, Inc., Bozeman

Sponsors

Lead Sponsor

CAGE Bio Inc.
All Listed Sponsors
collaborator

BioScience Laboratories, Inc.

INDUSTRY

lead

CAGE Bio Inc.

INDUSTRY

NCT04495920 - Clinical Evaluation of the Residual Antimicrobial Activity | Biotech Hunter | Biotech Hunter